Acrodermatitis chronica atrophicans overview: Difference between revisions
Kiran Singh (talk | contribs) |
No edit summary |
||
| Line 22: | Line 22: | ||
[[Category:Zoonoses]] | [[Category:Zoonoses]] | ||
[[Category:Spirochaetes]] | [[Category:Spirochaetes]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 19:07, 18 October 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]
|
Acrodermatitis chronica atrophicans Microchapters |
|
Differentiating Acrodermatitis chronica atrophicans from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acrodermatitis chronica atrophicans overview On the Web |
|
American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans overview |
|
Risk calculators and risk factors for Acrodermatitis chronica atrophicans overview |
Overview
Acrodermatitis chronica atrophicans is a skin rash indicative of the third or late stage of European Lyme borreliosis. It is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.
Historical Perspective
The first record of ACA was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it. Herxheimer and Hartmann described it in 1902 as a "tissue paper" like cutaneous atrophy.
Treatment
Medical Therapy
Treatment of ACA consists of antibiotics including doxycycline and penicillin for up to four weeks in the acute case.